RIPK3 and neoplasm: For this purpose, N‐ethyl‐N‐nitrosourea (ENU), a potent mutagen, was sequentially injected for three times to evaluate rapid tumor development between two groups (Ripk3+/+ versus Ripk3−/− mice group) (Figure 3A).